OSR Holdings reported that its subsidiary Woori IO’s Glucheck non‑invasive glucose monitoring system achieved more than 90 % of measurements with at least 85 % accuracy across all glucose ranges during a pilot study conducted at Korea University Guro Hospital from May 9 to September 12, 2023. The study enrolled 145 participants and used 140 datasets for calibration and validation, providing a robust evidence base for the technology’s performance.
The Glucheck system, available in both mouse‑type and stick‑type models, recorded 97 % of readings in the 100–149 mg/dL range and 100 % accuracy in the 200–249 mg/dL range. Across the full spectrum, fewer than 8 % of measurements fell below 74 % accuracy, a benchmark that many non‑invasive approaches have failed to meet. These figures represent a substantial technical milestone in a market that has long struggled to deliver reliable, pain‑free glucose monitoring.
The results reinforce OSR Holdings’ strategy to secure regulatory approval and commercialize the platform. A new proof‑of‑concept study with Samsung is underway, and the company plans a South Korean Ministry of Food and Drug Safety (MFDS)‑compliant clinical trial in the first half of 2026. The pilot’s success positions Woori IO to capture a share of the projected $47 billion continuous glucose monitoring market by 2034, and the partnership with Samsung signals strong industry endorsement of the technology.
Peter Hwang, CEO of OSR Holdings, said, “Our confidence in acquiring Woori IO is firmly grounded in the strength of its clinical performance.” He added that the breakthrough platform, coupled with high‑profile collaborations, places OSR Holdings as a potential first mover in the fast‑growing global CGM market.
The CGM market is expected to grow from roughly $40 billion in 2023 to $47 billion by 2034, with major players such as Abbott and Dexcom dominating the minimally invasive segment. Woori IO’s non‑invasive approach could disrupt this landscape, offering a pain‑free alternative that aligns with consumer demand for wearable health technology. The company’s progress also aligns with broader industry trends toward integration of glucose monitoring into smartwatches and other consumer devices.
With the pilot study’s success, OSR Holdings is poised to advance to the next regulatory phase and expand its commercial footprint. The company’s focus on rigorous clinical validation, strategic partnerships, and a clear path to market approval underscores its commitment to transforming diabetes care through innovative technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.